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Abstract
Background: African horse sickness virus (AHSV) causes a non-contagious, infectious disease in equids, with mortality rates
that can exceed 90% in susceptible horse populations. AHSV vaccines play a crucial role in the control of the disease;
however, there are concerns over the use of polyvalent live attenuated vaccines particularly in areas where AHSV is not
endemic. Therefore, it is important to consider alternative approaches for AHSV vaccine development. We have carried out a
pilot study to investigate the ability of recombinant modified vaccinia Ankara (MVA) vaccines expressing VP2, VP7 or NS3
genes of AHSV to stimulate immune responses against AHSV antigens in the horse.
Methodology/Principal Findings: VP2, VP7 and NS3 genes from AHSV-4/Madrid87 were cloned into the vaccinia transfer
vector pSC11 and recombinant MVA viruses generated. Antigen expression or transcription of the AHSV genes from cells
infected with the recombinant viruses was confirmed. Pairs of ponies were vaccinated with MVAVP2, MVAVP7 or MVANS3
and both MVA vector and AHSV antigen-specific antibody responses were analysed. Vaccination with MVAVP2 induced a
strong AHSV neutralising antibody response (VN titre up to a value of 2). MVAVP7 also induced AHSV antigen–specific
responses, detected by western blotting. NS3 specific antibody responses were not detected.
Conclusions: This pilot study demonstrates the immunogenicity of recombinant MVA vectored AHSV vaccines, in particular
MVAVP2, and indicates that further work to investigate whether these vaccines would confer protection from lethal AHSV
challenge in the horse is justifiable.
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Introduction
African horse sickness (AHS) is a non-contagious, infectious
disease of equids caused by African horse sickness virus (AHSV)
[1]. It is transmitted by the bite of certain Culicoides biting midge
species [2–4]. In susceptible populations of horses, mortality rates
can exceed 90% [5]. Nine different serotypes of the virus have
been identified, based on the specificity of its interactions with
neutralising antibodies in serum neutralisation assays [6].
The AHSV genome is composed of ten dsRNA segments, which
encode seven structural proteins VP 1–7 and four non-structural
proteins NS1, NS2, NS3 and NS3a [7]. AHSV particles are
organised as three concentric layers of proteins. The outer capsid
consists of two proteins VP2 and VP5. VP2 is the principal
serotype specific antigen of AHSV, and the majority of
neutralising epitopes are located on VP2 [7–9]. The virus core,
consists of two major proteins, VP7 which forms the core surface
layer, and VP3 which forms the innermost ‘subcore’ shell. The
subcore surrounds the 10 segments of the viral genome, and
contains three minor proteins VP1, VP4 and VP6 that form the
core associated transcriptase complexes [7].
AHSV is endemic in tropical and sub-tropical areas of Africa,
south of the Sahara [1], but epizootics of AHSV have also occurred
outside Africa, resulting in high mortality rates and severe economic
loses, such as those reported in the Middle East in 1959, or in North
Africa and Spain during 1969 and 1987 [10,11]. In the latter
outbreaks,anextensivevaccinationprogramandmovementcontrol
measures led to complete eradication of the disease [12,13].
Vaccination plays an essential role in the control and prevention
of the disease and vaccine development has been one of the main
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commercially available in South Africa, and have been developed
by cell-culture attenuation of the virus [14]. However, concerns
still exist over their use, particularly in those countries where the
disease is not endemic because of potential gene segment
reassortment between field and vaccine strains, potential reversion
to virulence and inability to distinguish vaccinated from infected
animals [1,14–17]. In the past, inactivated vaccines have been
shown to induce protective immunity [18,19], but are not readily
available.
For these reasons, research has focused on the development of
recombinant subunit and virus-like particle AHSV vaccines using
baculovirus expression systems. These recombinant vaccines in
conjunction with novel diagnostics allow the differentiation
between vaccinated and naturally infected animals and may
provide homologous protection against AHSV challenge [20,21].
However, these types of vaccines have yet to be used for
commercial vaccine production.
Another strategy that has been used for AHSV and other viral
vaccines is the use of live viral vectors. These have the ability to
introduce the recombinant gene product into the MHC class-I
pathway of antigen presentation and therefore prime cytotoxic T
cells as well as generate humoral immunity [22–24]. Most recently,
recombinant Venezuelan equine encephalitis virus-derived replicon
vectors,individually expressing the VP2andVP5genesofAHSV-4,
havebeendeveloped.However, in initial tests theseconstructs failed
to induce neutralizing antibodies in horses [25].
Poxvirus based vectors have been established as a potent system
for the development of candidate recombinant vaccines for many
viral diseases[26,27]. In the case ofAHSV, the potentialofpoxvirus
vector vaccination has been demonstrated using a recombinant
Vaccinia virus (Western Reserve (WR) strain) expressing AHSV-4
VP2 [28]. However, WR strain derived vaccinia viruses still
replicate in mammals and some concerns exist over their safety. For
this reason, the use of poxvirus vectors with limited replication
capacity, are preferred for vaccine development.
The modified vaccinia Ankara (MVA) strain was derived after
more than 570 passages in primary chick embryo fibroblasts [29].
The resulting virus has lost the ability to productively infect
mammalian cells [30]. Virus replication is blocked at a late stage of
morphogenesis in mammalian cells, leaving expression of late, as
well as early, viral genes unimpaired [29]. MVA was shown to be
non-pathogenic even for immunodeficient animals and recombi-
nant viruses were found to be able to synthesise high levels of a
foreign protein in human cells, demonstrating the potential of
MVA as a safe and efficient expression vector [29]. Recent studies
have also provided evidence for the safety and immunogenicity of
recombinant modified vaccinia Ankara (MVA) in ponies [31,32].
For these reasons recombinant MVA was chosen as a vector for
AHSV antigens.
Due to the lethality of AHSV challenge studies and the number
of animals that would be required it was deemed important to
carry out this pilot investigation to determine whether it is possible
to induce an AHSV-specific immune response in ponies by
vaccination with recombinant MVA viruses expressing AHSV
proteins. For this we constructed three recombinant MVA viruses
expressing three antigens of AHSV-4: VP2, VP7 and NS3, and
characterised the antibody responses that were generated. These
antigens were chosen for several reasons. Studies using recombi-
nant VP2 vaccines in horses have demonstrated that VP2 induces
a neutralising antibody response, which is serotype specific,
affording protection against homologous virus challenge [21,28].
AHSV-9 VP7 has been shown to provide protection in the mouse
model against a heterologous challenge with a known lethal dose
of AHSV-7 [33]. NS3 was chosen as it is known to stimulate
antibody responses in the horse [34,35] and studies with closely
related bluetongue (BTV) have demonstrated that NS3 may also
be a CTL target for BTV-immune sheep [36,37].
The results of this study demonstrate the immunogenicity of
recombinant MVA vectored AHSV antigens, in particular
MVAVP2. Further work with MVANS3 is needed, however, the
use of MVAVP2 and MVA VP7 in a lethal challenge study in the
future would be justified.
Results
Characterisation of recombinant MVA viruses
Confirmation of gene expression of the recombinant MVA
viruses used as vaccines in this study was tested in quail
fibrosarcoma (QT35, ECACC Ref. No. 93120832) and equine
skin fibroblasts (ESF) infected cells by detection of the expressed
AHSV gene product, or, where no antibody was available,
detection of specific RNA transcripts. Both VP2 and VP7 were
detected in infected cell lysates by western blotting with VP2 and
VP7 specific monoclonal antibodies at the expected molecular
weights of ,116 and ,38 kDa, respectively (Figure 1). The
detection signal for VP2 was stronger in QT35 than in ESF cells,
revealing a potential difference in expression levels of this protein
between these cell lines. Expression of VP7 was also confirmed by
indirect immunofluorescence (data not shown). Expression of NS3
protein from MVANS3 was not tested due to a lack of NS3-
specific antibody reagents. The functionality of the vaccinia P7.5
NS3 expression cassette was confirmed by detection of NS3-
specific RNA sequences at 4 hours post-infection in MVANS3
infected QT35 and ESF cells by RT-PCR. The cDNA amplicons
generated were the expected size (670 bp). The absence of
contaminating genomic DNA in all of the RNA extracts was
confirmed by negative PCR results using RNA templates
(Figure 2).
Analysis of antibody responses to MVA
Following an initial vaccination with recombinant MVA viruses,
all of the ponies displayed transient inflammation at the sites of
inoculation and slight elevation of rectal temperatures. This was not
observed following subsequent inoculations. All the ponies were
seronegative for MVA prior to vaccination. Following the initial
dose, a slight increase in MVA specific antibody levels was observed
by 21 days post vaccination in four animals, but had declined again
by day 35. Antibodies against MVA were detected in all animals
after the second vaccination (day 35), the serum titres ranging from
0.75 to 2.25 on day 42 but these had declined by day 77. A third
dose boosted the antibodies again, and the range of titres was
narrower than after the second vaccination (Figure 3).
Analysis of antibody responses to AHSV antigens
Western blots. An antibody response against AHSV VP2
was detected in both MVAVP2 vaccinates by western blotting
using sera taken at 42 and 84 days post vaccination (Figure 4).
Recombinant baculovirus expressed VP2-V5 was similarly
detected at ,116 kDa with the anti-V5 mAb. For both ponies,
the VP2-V5-specific band was more evident using the samples
collected on day 84 (after the third vaccination) than on day 42
(after the second vaccination).
An antibody response against VP7 was detected at 42 and 84
days post vaccination in one of the two MVAVP7 vaccinates (pony
5859) (Figure 5), with a faint band corresponding to VP7
(,38 kDa) observed for sera collected on days 42 and 84. No
antibodies to VP7 were detected in the other MVAVP7 vaccinated
AHSV Recombinant Vaccine
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itated NS3 were detected in either of the ponies vaccinated with
MVANS3 (data not shown).
Virus neutralisation test. The virus outer capsid protein
VP2 is the dominant AHSV antigen and the main target of
homologous virus neutralising (VN) antibodies. Therefore, success
Figure 1. Detection of MVAVP2 or MVAVP7-expressed VP2 and VP7 protein, respectively, within QT35 and ESF cells. Cell lysates of
uninfected cells (lanes 1,3,5 and 7) and cells infected at high MOI with MVA-VP2 (lanes 2 and 4) or MVA-VP7 (lanes 6 and 8), and harvested at 24 hours
post-infection, were separated by SDS-PAGE on 10% gels. Immunoblotting was conducted with either anti-VP2 mAb (lanes 1–4) or anti-VP7 mAb
(lanes 5–8).
doi:10.1371/journal.pone.0005997.g001
Figure 2. Detection of NS3 RNA transcripts from MVANS3. 1% agarose gels showing RT-PCR and PCR products using RNA templates extracted
from MVA infected QT35 and ESF cells 4 hours post infection. Tracks 1–3 QT35 RNA extract RT-PCR products. Tracks 4–6 QT35 RNA extract PCR
products. Tracks 7–9 ESF RNA extract RT-PCR products. Tracks 10–12 ESF RNA extract PCR products. Expected product size 670 bp. Tracks 1, 4, 7, & 10
MVANS3; 2, 5, 8, & 11 MVA wild type; 3, 6, 9, & 12 pSC11NS3 plasmid.
doi:10.1371/journal.pone.0005997.g002
AHSV Recombinant Vaccine
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whether a VN antibody response was induced. The results of the
VN test are shown in Table 1. Both ponies were seronegative prior
to vaccination. Following the initial vaccination the serum VN
antibody titres in both ponies were low. However, following the
first MVAVP2 boost (day 35) VN titres increased rapidly
(maximum VN titre of 2). The titres remained at a similar level
until at least day 84.
Discussion
In recent years, there has been an unprecedented emergence of
the Culicoides transmitted pathogen BTV in Europe and the
Mediterranean. This has been attributed to the northward
expansion of the major BTV vector, Culicoides imicola, possibly
influenced by climate change; as well as the involvement of
indigenous European Culicoides species [38,39]. Due to the
similarities between BT and AHS viruses and their vectors, it
has been suggested that should AHSV incur into Europe there is
the potential for it to become as widespread as BTV [39,40]. As
there are concerns over the use of modified live AHSV vaccines,
the development of efficacious and safer AHSV vaccines, suitable
for use in both endemic and non-endemic regions, is therefore an
important focus of AHSV research. Poxvirus vectored vaccines,
with enhanced safety due to limited replication are of particular
interest. Indeed, recombinant canarypox virus based vaccines for
the prevention of equine influenza, West Nile virus or equine
herpesvirus infections have already been developed for use in
horses, and for the prevention of the closely related BTV in sheep
[41–44]. Vaccination of horses with recombinant MVA based
vectors has also been shown to be an effective means of inducing
protective immunity to influenza virus infection [32,45].
A recent study comparing recombinant canarypox and MVA
vectors has demonstrated that antigen production by recombinant
MVA was greater than that from recombinant canarypox virus in
certain mammalian cell lines and primary human cells tested [46].
This observation was primarily due to a longer duration of antigen
production in recombinant MVA-infected cells. Antigen produc-
tion by MVA was also noted to be greater in human dendritic
cells, and resulted in enhanced T-cell stimulation in an in vitro
antigen presentation assay [46]. Therefore, the potential of
recombinant MVA viruses, expressing AHSV proteins, to induce
AHSV-specific immune response in ponies was investigated.
In this study we successfully generated three recombinant MVA
viruses, MVAVP2, MVAVP7 and MVANS3, Western blots using
both MVAVP2 and MVAVP7 infected QT35 and ESF cell lysates
confirmed that these recombinant viruses were infectious and able
to express the AHSV antigens in equine cells. We did not have
access to NS3-specific antibodies and therefore it was difficult to
evaluate NS3 protein expression in MVA infected cells. However,
detection of NS3 specific sequences by RT-PCR from total RNA
extracted from QT35 and ESF cells infected with MVANS3
suggested the expression cassette was functional and so the
recombinant MVANS3 was used in the vaccination studies.
Following vaccination with recombinant MVA viruses, all the
ponies remained healthy, although transient inflammation of the
inoculation sites and elevation of rectal temperatures were
observed after the initial vaccinations. This is suggestive of an
active infection, and was probably associated with the MVA
vector, as subsequent inoculations did not induce these reactions
indicating pre-existing immunity to the MVA. Indeed, MVA-
specific neutralising antibody responses were demonstrated in all
ponies after the initial vaccination. After subsequent vaccinations
all the ponies showed an anamnestic response and produced
higher levels of MVA neutralising antibodies. This is consistent
with other work carried out in the horse [31].
Following the second vaccination (day 42), VP2 specific
antibody responses were demonstrated for both MVAVP2-
vaccinated ponies by western blotting. The neutralising activity
of the antibody response was confirmed by AHSV VN test, with
titres rising to 1.8/2 units (ponies 5843 & 4246 respectively) after
the second vaccination. This is a promising result, because in a
previous study using recombinant vaccinia expressing AHSV-4
VP2, significant neutralising titres were not observed in vaccinated
horses until after the third inoculation [28]. Furthermore, the VN
Figure 3. Development of neutralising antibodies against MVA following vaccination. MVA plaque reduction neutralisation titre of sera
taken from ponies following initial vaccination with recombinant MVA and two subsequent boosts. Arrows denote days of vaccination.
doi:10.1371/journal.pone.0005997.g003
AHSV Recombinant Vaccine
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in the literature, which have been observed to provide protection
against lethal AHSV challenge [21,28].
Antibody responses following MVAVP7 immunisation were also
observed, albeit in only one of the two vaccinates. In the mouse
model, mice vaccinated with recombinant AHSV VP7 have also
shown very variable anti-VP7 antibody responses. However, VP7
vaccination still conferred protection against heterologous challenge
with a lethal dose of AHSV and it was suggested that this protection
was unlikely to be due to the antibody-mediated immune response
alone, but may have been related to cell-mediated responses [33].
Additional work to investigate whether this is the case in the horse is
therefore required.
Neither of the ponies vaccinated with MVANS3 developed NS3
specific antibody responses during the study period, despite
showing clear neutralising antibody responses to the MVA vector.
Although NS3 mRNA could be demonstrated in vitro, the
expression of the NS3 protein could not be confirmed. It is
possible that the protein was expressed at very low levels due to
rapid degradation after translation. Previous studies of BTV-NS3
have indicated that it is poorly expressed in mammalian systems
infected with BTV although it is expressed well in insect cell
systems [47,48]. The low expression of NS3 in mammalian cells
may therefore be a normal property of the AHSV Segment-10
mRNA.
The impact of previous immunity to both replication competent
and replication deficient vaccinia virus has been investigated in
several studies and is suggested to reduce the effectiveness of
subsequent vaccinations [22,24,49,50]. The second MVAVP2
vaccination in this study was found to boost VP2 specific antibody
titres, despite a pre-existing antibody response to the MVA vector,
although the third vaccination did not increase the VNAb
response any further. Therefore, it may be necessary to investigate
methods to enhance immune responses generated against the
AHSV antigens. The use of DNA priming prior to vaccination
with recombinant MVA has been used successfully in several
studies [24,51,52] and could be applied to future work with the
recombinant MVA AHSV vaccines.
In summary, the ability of recombinant MVA viruses encoding
AHSV proteins (VP2, VP7, and NS3) to induce AHSV antigen-
specific antibody responses was investigated. The confirmation of
antibody responses against VP2 and VP7, in particular induction
Figure 4. Detection of immunoprecipitated, recombinant-baculovirus-expressed VP2V5 with MVAVP2-vaccinated pony serum.
Lysates of uninfected Sf9 cells (lanes 1,3,5,7 and 9) and Sf9 cells infected with recombinant baculovirus FBVP2-V5 were immunoprecipitated with anti-
V5tag mAb and Protein G agarose. The immunoprecipitates were separated by SDS-PAGE on 10% gels, and immunoblotted with MVAVP2 vaccinated
pony sera (4256, 5483) (lanes 1–8) or anti-V5tag mAb (lanes 9 & 10). The pony sera tested were derived from a pre-vaccination control bleed (lanes 1 &
2) and three post-vaccination bleeds (lanes 3–8) from days 21, 42, and 84, respectively. A non-specific band was present to some extent in each lane
at ,50 KDa.
doi:10.1371/journal.pone.0005997.g004
AHSV Recombinant Vaccine
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5997of strong virus neutralising antibody by MVAVP2, warrant the
further investigation of MVA vectored AHSV vaccines, to
investigate whether they also induce cellular immune responses
and ultimately induce protection from both homologous and
heterologous AHSV challenge.
Materials and Methods
Generation of recombinant MVA viruses expressing VP2,
VP7 and NS3
The cDNA copies of genome segments 2, 7 and 10 from the
Madrid 1987 strain of AHSV-4 (IAH reference collection number:
SPA1987/01) [53] were generated using previously described
methods [54] and cloned into plasmid pT7-Blue (Novagen,
Madison, USA) using standard molecular biology techniques.
The AHSV genes were subcloned into the vaccinia transfer
vector pSC11 downstream of the vaccinia P7.5 promoter [55], to
generate pSC11VP2, pSC11VP7 and pSC11NS3. Integration of
the expression cassettes into the thymidine kinase (TK) locus of
MVA, was achieved by infecting QT35 cells grown in Glasgow
minimum essential medium (GMEM) supplemented with 10%
foetal calf serum, 10% tryptose phosphate broth, 2 mM L-
glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin
(all from Sigma-Aldrich, Dorset, UK), with wild type MVA (MOI
0.05 for 1 h, 37uC) followed by transfection with pSC11VP2,
pSC11VP7 or pSC11NS3 using Lipofectamine 2000 (Invitrogen,
Paisley, UK). Cells were incubated for 48–72 hours at 37uC, 5%
CO2. The cells were scraped from the plastic and pelleted at
15006g for 10 minutes. The pellet was resuspended in 1 ml serum
free GMEM and freeze-thawed three times to lyse the cells and
release the cell-associated virus particles.
Recombinant viruses, denoted as MVAVP2, MVAVP7 and
MVANS3, were purified by selecting for Lac Z marker gene
expression and TK negative phenotype, using methods that have
been described previously [55]. Pure recombinant MVAVP2,
MVAVP7 and MVANS3 virus stocks were propagated in QT35
cells, titrated and used for vaccination of ponies. The MVANS3
virus stock was purified once over a sucrose cushion as described
previously [32]. MVAVP2 and MVAVP7 virus stocks were not
purified before vaccination.
Confirmation of AHSV gene expression from
recombinant MVA
MVANS3ReverseTranscriptase(RT)-PCR. TotalRNAwas
extracted from ESF and QT35 cells infected with the recombinant
MVA using RNeasy mini kit (Qiagen, Crawley, UK) and DNase
treated with the Turbo DNA-free kit (Ambion, Huntindon, UK).
Figure 5. Detection of recombinant baculovirus-expressed VP7 with MVA-VP7-vaccinated pony serum. A semi-purified preparation of
recombinant baculovirus FBVP7-expressed VP7 was separated by by SDS-PAGE on 10% gels, and immunoblotted with MVA-VP7-vaccinated pony sera
(lanes 1–4) or anti-VP7 mAb (lane 5). The pony sera tested were derived from a pre-vaccination control bleed (lane 1) and three post-vaccination
bleeds (lanes 2–4) from days 21, 42, and 84, respectively.
doi:10.1371/journal.pone.0005997.g005
Table 1. AHSV-neutralising antibody responses in ponies
vaccinated with MVAVP2.
Post-vaccination titres*
Day Pony 5483 Pony 4246
(V1) 0 neg neg
28 0.4 0.6
(V2) 35 0.3 0.5
42 1.8 1.9
56 1.6 2
(V3) 77 1.6 2
84 1.7 1.7
91 1.35 N.T.
Positive control 2.5
Negative Control neg
*Expressed as the reciprocal of the highest dilution that provided .50%
protection of the Vero cell monolayer.
doi:10.1371/journal.pone.0005997.t001
AHSV Recombinant Vaccine
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kit (Invitrogen), with 5 ml RNA template, using NS3 specific primers
NS3f (59-ACTGTGGATCCTCATGAATCTAGCTGCAA-39)
and NS3r (59-GATACGAATTCCTAGCTTTCGCCATAC-39)a s
forward and reverse primers, respectively. A PCR was also set up
using the same primer set as for the RT-PCR to confirm the absence
of DNA in the samples.
Analysis of VP2 and VP7 expression by recombinant MVA
using Western blotting
2610
6 QT35 cells or ESF were mock infected or infected with
MVAVP2 or MVAVP7 (MOI of 3), and harvested at 24 h post-
infection. Cell lysates were prepared using 200 ml of ice-cold
solubilisation buffer [20 mM Tris-HCL, 150 mM NaCl, 1%
sodium deoxycholate, 1% Tergitol, 0.1%, SDS, 2 mM EDTA (all
supplied by Sigma-Aldrich), supplemented with protease inhibitors
(Roche, Mannheim, Germany) prior to use], centrifuged at
179006g for 15 minutes at 4uC, and the supernatants retained.
Lysates were mixed 1:1 with Laemmli sample buffer, heated at
95uC for 5 minutes, and separated by SDS-PAGE on 10%
polyacrylamide gels. The separated protein was transferred to
nitrocellulose, blocked overnight at 4uC with 0.05% Tween20/
phosphate buffered saline (PBS-T) supplemented with 5% bovine
serum albumin (Sigma-Aldrich) and 5% non-fat milk powder, prior
to immunodetection.Blotswere probed with monoclonalantibodies
(mAb) 8BC2 and 10AB1 specific for VP2 and VP7 of AHSV-4
respectively [56,57] provided by INGENASA (Madrid, Spain).
Following extensive washing with PBS-T, membranes were
incubated with a goat anti-mouse horseradish peroxidase (HRP)-
conjugated secondary antibody (Dako, Glostrup, Denmark) diluted
1:1000 in blocking buffer, again washed thoroughly in PBS-T, and
bound antibodies visualised with an enhanced chemiluminescence
kit(AmershamBiosciences,Little Chalfont,UK).Proteinseparation
was visualized with rainbow pre-stained markers (Bio-Rad Labo-
ratories, Hemel Hempstead, UK) and biotinylated protein markers
(Bio-Rad Laboratories) were additionally used for marker-visual-
isation on ECL Hyperfilm (Amersham Biosciences).
Generation of recombinant baculoviruses expressing
AHSV proteins
A baculovirus expression system was used in order to obtain a
source of antigens for use in immunological assays. The VP2, VP7
and NS3 genes were PCR amplified with gene specific primers
containing restriction enzyme recognition sequences. The VP2 was
amplified using primers 59-CTTGAATTCGGACCATGGC-
GTCCGAGTTTGGAATATTG-39 and 59-GAAGAATTCCT-
TCCGTTTTTGCGAGTAACTTCG-39; VP7 was amplified with
primers 59-GTTCGCGGCCGCACCATGGACGCGATAGCAG-
CAAG-39 and 59-GTTCGCGGCCGCAATCTAGTGGTAGG-
CTGCTAG-39; and NS3 was amplified with 59-ATCGGATCCAC-
CATGAATCTAGCTG-39 and 59-ATATTCTCGAGTGCTT-
TCGCCATACT-39. In the case of VP2 and NS3 the genes were
antigenically tagged. The carboxyterminal V5 antigen tags were
generated by subcloning the PCR amplicons into the MCS site of
plasmid pcDNA6/V5-His C (Invitrogen) in frame with the tag
sequences. Subsequently the pcDNA6VP2 and pcDNA6NS3 were
digested with PmeI (New England Biolabs, Ipswich, UK) and the V5
tagged versions of VP2 and NS3 ligated into the MCS site of
pVL1393 (Invitrogen) downstream of the polyhedrin promoter. In
the case of VP7, the amplicon was digested directly with restriction
enzyme and cloned into the MCS site of pVL1393.
Recombinant baculoviruses were generated by homologous
recombination, according to manufacturer’s instructions, using
flashBAC (NextGen Sciences Ltd, Huntingdon, UK), a baculo-
virus circular DNA lacking part of the essential gene ORF1629.
Briefly, Sf9 cells seeded in EX-CELL 420 serum-free medium
(Sigma-Aldrich) were co-transfected with the baculovirus
pVL1393 shuttle vectors, Cellfectin (Invitrogen) and flashBAC
and incubated for 5 days at 28uC. Following the incubation period
the medium containing the seed stock of recombinant baculovirus
was harvested.
The recombinant baculoviruses, denoted as FBVP2-V5, FBVP7
and FBNS3-V5 were grown in Sf9 cells, cells pelleted by low speed
centrifugation and lysed in solubilisation buffer. This was used as
an antigen source in Western blots to analyse the antibody
responses of the vaccinated ponies.
Ponies, vaccination procedures and sampling
Six Welsh mountain ponies were divided into three groups of two
animals, each group being vaccinated with MVAVP2 (ponies 4256
& 5483),MVAVP7(ponies5859& 5717)orMVANS3(ponies0758
& 0907). Vaccinations were performed by administering a dose of
10
8 plaque forming units (pfu) on days 0, 35 and 77, using a
combination of intramuscular and intradermal routes. Intradermal
vaccination was performed using a needle-less injection device
(Injex, Anaheim, USA). Serum samples were collected weekly
during the vaccination study for analysis of the antibody response.
All work involving experimental ponies was performed under a
Home Office Project Licence and had been approved by the
Animal Health Trust’s Ethical Review Committee.
Analysis of MVA-specific antibody responses by plaque
reduction neutralisation test (PRNT)
Anti-vaccinia MVA antibody responses were analysed in the
vaccinated animals by a plaque reduction neutralisation test.
Doubling dilutions of serum samples collected from the vaccinated
animals were made in 100 ml volume of serum-free growth
medium in triplicate wells of 96-well plates and incubated with
10
2 pfu/100 ml of MVANS3 for 2 hours at 37uC, 5% CO2. One
hundred microlitres of the sera-virus suspension was then added to
96-well plates containing pre-formed monolayers of QT35 cells.
After 2 hours incubation 100 ml of growth medium was added and
the plates incubated overnight at 37uC, 5% CO2. The following
day the medium was removed from the wells, the cells fixed with
0.5% glutaraldehyde (Sigma-Aldrich), washed twice with 2 mM
magnesium chloride (Sigma-Aldrich) in PBS and stained with an
X-gal sensitive stain (10 mM potassium ferricyanide/ferrocyanide,
0.02% Tergitol, 0.01% sodium deoxycholate, 0.5 mg/ml X-gal,
2 mM magnesium chloride in PBS). After 30 minutes incubation
at 37uC, the plates were washed again and the number of blue
plaques formed in each well was determined. Virus infectivity was
considered to be neutralised in each well when more than a 90%
reduction in the number of plaques was observed relative to the
positive control. Serum titres were calculated according to the
Karber formula [58], the highest serum dilution showing virus
neutralisation being considered as the end-point.
Analysis of AHSV-specific antibody responses by Western
blotting
An immunoprecipitation method was employed to obtain a
partially purified and concentrated source of VP2 or NS3 antigen,
respectively. Uninfected, FBVP2-V5 or FBNS3-V5-infected Sf9
cell lysates were immunoprecipitated with anti-V5 mAb. Lysates
were first pre-adsorbed against Protein G agarose (Calbiochem,
Darmstadt, Germany) and then mixed overnight at 4uC with
Protein G agarose and anti-V5 mAb (Invitrogen), according to the
AHSV Recombinant Vaccine
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solubilisation buffer, then mixed 1:1 with 26 Laemmli sample
buffer. The immunoprecipitates were eluted from the protein G
agarose by heating at 85uC for 5 minutes. The antigen source for
VP7 consisted of partially purified VP7 crystals, generated using
previously described methods [59]. Immunoprecipitates of VP2
and NS3, and purified VP7 were separated by SDS-page on 10%
polyacrylamide gels, and Western blotting conducted as described
above.
Blots were probed with equine serum samples (1:100) or mAb to
VP2 (undiluted), VP7 (1:100), or anti-V5 antibody (1:5000),
diluted in blocking buffer. Equine sera labelled membranes were
probed with a goat anti-horse HRP-conjugated secondary
antibody diluted 1:10,000 in blocking buffer (Jackson ImmunoR-
esearch Laboratories, West Grove, USA).
Analysis of AHSV-VP2-specific antibody responses by
AHSV virus neutralisation test
Serum samples from the MVAVP2 vaccinates, AHSV seropos-
itive (positive control) and AHSV seronegative horses (negative
control) were heat inactivated for 30 minutes at 56uC, and serially
diluted in quadruplicate wells of a 96-well microtitre plates using
DMEM [Dulbecco modified minimum essential medium supple-
mented with 0.6% Penicillin/Streptomycin (all supplied by Sigma-
Aldrich)] as diluent. The serum dilutions were incubated with 100
TCID50 of AHSV serotype 4 at 37uC for 1 hour and then
overnight at 4uC. A virus titration in the absence of horse serum
was made to confirm that the virus dose per well was 100 TCID50.
The following day 2610
4 Vero cells in RPMI medium
supplemented with 0.6% Penicillin/Streptomycin, 0.6% L-gluta-
mine and 5% adult bovine serum (all supplied by Sigma-Aldrich),
were added to every well and the plates incubated for 3 days at
37uC, 5% CO2. The plates were checked for AHSV cytopathic
effect (cpe), with the end-point of the assay being taken as the
highest dilution that prevented AHSV cpe in the wells. Serum
titres were then calculated by the Karber formula [58].
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